Semaglutide Streamlined to Single Pen Monthly Injection Type 2 Diabetes

Novo Nordisk has streamlined its 1 mg semaglutide (Ozempic) injection for type 2 diabetes, reducing the need for 2 pens to 1 each month, according to a press release.

The device remains the same, but will have a larger cartridge that contains 4, 1 mg doses. In addition, the new packaging will provide 1 pen and 4 needles to accommodate the 4 injections per 28 days (1 injection per week). The device is not a single-use pen and should not be thrown out until 4 doses are administered.

The single monthly pen will become available starting in April, and patients may need to receive a new prescription from their health care provider in order to receive the new packaging. Further, patients should continue to take their medication as prescribed by their health care provider, according to the press release.

REFERENCE

Novo Nordisk transitions to single pen for monthly supply of Ozempic® (semaglutide) injection 1 mg [email]. Published April 1, 2021. Accessed April 5, 2021.